The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...

The recent acquisitions by pharmaceutical giants Johnson & Johnson and Bristol Myers Squibb, worth a combined $28billion, ...

Africa’s pharmaceutical future is at a critical juncture with developments shedding light on the continent’s reliance on external aid for vaccine access. The Trump administration’s initial freeze on ...

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...

Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Leading global drugmakers such as MSD Pharmaceuticals, Novartis, AstraZeneca, and Pfizer stand to benefit as it opens new ...

Budget 2025: Seeks to further amend notification No. 16/2017-Customs, dated the 20th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified ...

To give some idea of the sheer size of Johnson & Johnson, a glance at its reported sales figure is revealing. In the fourth ...

The list of 36 drugs, which are exempt from basic customs duty, includes many expensive and imported medicines that can ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other long ...